<DOC>
	<DOC>NCT02899091</DOC>
	<brief_summary>The objective of the study is to evaluate the safety and the potential therapeutic effects of CB-AC-02 Intravenous Transplantation in patients with Alzheimer' disease comprised of 2 treatment cohorts:</brief_summary>
	<brief_title>Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1. Korean male or female at 50+ years of age at the time of screening visit 2. Diagnosis of Probable Alzheimer disease (probable AD) according to NINCDSADRDA criteria at Screening visit 3. Positive for Amyloid on amyloidligand PET 4. A subject with the imaging findings of Alzheimer's disease as confirmed by MRI or PET Presence of brain atrophy on brain MRI by visual assessment Presence of reduced brain glucose metabolism in bilateral temporalparietal lobe on FDGPET 5. Korea MiniMental State Examination (KMMSE) score of 1026 at time of screening visit 6. Presence of caregiver who can provide information on the subject's condition 7. Subject who has been taking stable dose of Alzheimer medication for last 2 months or more 8. Subject who is informed of the clinical trial and signs a consent form (if unable to sign, a consent from a legally acceptable representative is required) 1. Concurrent Dementia as a result of other disorders [i.e. infectious disease of the central nervous system such as HIV, syphilis, head injury, CreutzfeldJacob disease, Picks disease, Huntington's disease, Parkinson's disease, other subdural hematoma, hydrocephalus and structural brain lesions, drug addiction, alcoholism, substance abuse, thyroid disease, parathyroid disease, vitamins and other nutritional deficiencies and vascular etc.] 2. Subject with vascular dementia as determined by the clinical criteria of DSMIV and the imaging criteria of Erkinkuntii 3. Subject with severe white matter hyperintensities (i.e. ≥ 25mm of the deep white matter and ≥ 10mm of the periventricular capping/banding in lengths) 4. Abnormal laboratory findings at screening visit: A. ALT or AST ≥ 2.5 times the upper limit of normal value B. Serum creatinine ≥ 1.5 times the upper limit of normal value C. Total bilirubin ≥ 2 times the upper limit of normal value D. Total WBC counts &lt; 3,000/㎣ E. Hemoglobin &lt;9.5g/dL in men or &lt;9.0g/dL in women F. Platelet count &lt; 150,000/㎣ at screening visit G. PT (INR) ≥ 1.5 or aPTT ≥ 1.5 times the upper limit of normal value 5. Subjects who are positive for HIV, syphilis or active HBV, HCV infection 6. Subjects in poor medical condition or subjects with severe cardiovascular, gastrointestinal, pulmonary or endocrinologic disease A. Suspected active active lung disease on chest Xray at screening visit B. Diagnosis of cancer (except for the subjects who remains in complete remission for 5 years or more ) 7. Subject with concurrent unstable psychiatric disorder (i.e. severe depression, or schizophrenia, or bipolar disorder, etc) 8. Pregnant or lactating women 9. Women of childbearing age who reject to practice contraception with one of the following methods Use a condom Use of contraceptive (oral, dermal, or injectable) Use an intrauterine contraceptive device 10. Subjects with a history of alcohol abuse (&gt;30g/day) or drug abuse 11. Subjects who cannot undergo any of the tests performed in this clinical trial (for example, MRI, CT, PET, CSF study) 12. Subjects with known allergies to protein products (Bovine serum), antibiotics (gentamycin) or DMSO 13. Subjects whom the principal investigator considers inappropriate for participation in theis study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>Mesenchymal Stem cells</keyword>
</DOC>